NICE now recommends the use of Janssen Pharmaceuticals' drug abiraterone for prostate cancer patients prior to chemotherapy. The change in decision was prompted by new evidence of the drug's cost-effectiveness.
NICE now recommends the use of Janssen Pharmaceuticals' drug abiraterone for prostate cancer patients prior to chemotherapy. The change in decision was prompted by new evidence of the drug's cost-effectiveness.
Share this Article
Recommended